Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2A | O00443 | 18/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.83 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.83 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002947 | 1.00 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3C2GHTTHSD17B10 | |
| SCHEMBL30002534 | 0.91 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL21586332 | 0.91 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL30003110 | 0.86 | PIK3C2A (0.75) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL30002516 | 0.86 | PIK3C2A (0.75) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL21586341 | 0.86 | PIK3C2A (0.75) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL21586310 | 0.86 | PIK3C2A (0.75) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL21586309 | 0.86 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL30003012 | 0.86 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3C2G | |
| SCHEMBL21586346 | 0.83 | PIK3C2A (1.00) | PIK3C2APIK3C2BPIK3C2G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-03-11 | — | — | US | disclosed |
| EP-3802530-B1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN EV (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2022-10-20 | — | — | US | disclosed |
| EP-3802530-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Forschungsverbund Berlin E.V. (DE) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019234237-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019234237-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3CD, PIK3C2B | PIK3C2A 5/4885PIK3C2B 3/4885PIK3C2G 27/4885 |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2B | PIK3C2A 5/4885PIK3C2B 3/4885PIK3C2G 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.